Granules India informs about update on GPI facility

03 Apr 2024 Evaluate
With respect to communication dated December 16, 2023, regarding the US FDA inspection of the facility of Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA and issuance of Form 483 with 5 observations; Granules India has informed that GPI has received a communication from the US FDA indicating the inspection classification as ‘Voluntary Action Indicated’ (VAI). The VAI inspection classification indicates that the US FDA will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

The above information is a part of company’s filings submitted to BSE.

Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.